| 1. |
Yu-Wai-Man P, Votruba M, Moore AT, et al. Treatment strategies for inherited optic neuropathies: past, present and future[J]. Eye (Lond), 2014, 28(5): 521-537. DOI: 10.1038/eye.2014.37.
|
| 2. |
Yang S, Chen C, Yuan JJ, et al. Multilocus mitochondrial mutations do not directly affect the efficacy of gene therapy for Leber hereditary optic neuropathy[J]. J Neuroophthalmol, 2020, 40(1): 22-29. DOI: 10.1097/wno.0000000000000797.
|
| 3. |
Jiang P, Liang M, Zhang J, et al. Prevalence of mitochondrial ND4 mutations in 1281 Han Chinese subjects with Leber's hereditary optic neuropathy[J]. Invest Ophthalmol Vis Sci, 2015, 56(8): 4778-4788. DOI: 10.1167/iovs.14-16158.
|
| 4. |
Jia X, Li S, Wang P, et al. mtDNA m. 3635G>A may be classified as a common primary mutation for Leber hereditary optic neuropathy in the Chinese population[J]. Biochem Biophys Res Commun, 2010, 403(2): 237-241. DOI: 10.1016/j.bbrc.2010.11.017.
|
| 5. |
張娟娟, 張增君, 付汝寧, 等. MT-ND1m. 3635G>A突變在Leber遺傳性視神經病變發病中的作用[J]. 中華醫學遺傳學雜志, 2016, 33(6): 747-751. DOI: 10.3760/cma.j.issn.1003-9406.2016.06.001.Zhang JJ, Zhang ZJ, Fu R, et al. Role of MT-ND1m. 3635G>A mutation in the pathogenesis of Leber hereditary optic neuropathy[J]. Chin J Med Genet, 2016, 33(6): 747-751. DOI: 10.3760/cma.j.issn.1003-9406.2016.06.001.
|
| 6. |
Lyseng-Williamson KA. Idebenone: a review in Leber's hereditary optic neuropathy[J]. Drugs, 2016, 76(7): 805-813. DOI: 10.1007/s40265-016-0574-3.
|
| 7. |
Carelli V, Carbonelli M, de Coo IF, etal. International consensus statement on the clinical and therapeutic management of leber hereditary optic neuropathy[J]. J Neuroophthalmol, 2017, 37(4): 371-381. DOI: 10.1097/WNO.0000000000000570.
|
| 8. |
Chen BS, Yu-Wai-Man P, Newman NJ. Developments in the treatment of Leber hereditary optic neuropathy[J]. Curr Neurol Neurosci Rep, 2022, 22(12): 881-892. DOI: 10.1007/s11910-022-01246-y.
|
| 9. |
Vignal S, Uretsky S, Fitoussi S, et al. Safety of rAVV2/2-ND4 gene therapy for Leber's hereditary optic neuropathy[J]. Ophthalmology, 2018, 125(6): 945-947. DOI: 10.1016/j.ophtha.2017.12.036.
|
| 10. |
王佳偉, 趙娟. Leber遺傳性視神經病變診斷和治療專家共識[J]. 眼科, 2019, 28(5): 328-335. DOI: 10.13281/j.cnki.issn.1004-4469.2019.05.003.Wang JW, Zhao J. Expert consensus on the diagnosis and treatment of Leber hereditary optic neuropathy[J]. Ophthalmology, 2019, 28(5): 328-335. DOI: 10.13281/j.cnki.issn.1004-4469.2019.05.003.
|
| 11. |
Newman NJ, Yu-Wai-Man P, Carelli V, et al. Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset[J]. Ophthalmology, 2021, 128(5): 649-660. DOI: 10.1016/j.ophtha.2020.12.012.
|
| 12. |
Sahel JA, Newman NJ, Yu-Wai-Man P, et al. Gene therapies for the treatment of Leber hereditary optic neuropathy[J]. Int Ophthalmol Clin, 2021, 61(4): 195-208. DOI: 10.1097/IIO.0000000000000364.
|
| 13. |
Vignal-Clermont C, Girmens JF, Audo I, et al. Safety of intravitreal gene therapy for treatment of subjects with Leber hereditary optic neuropathy due to mutations in the mitochondrial ND4 gene: the REVEAL study[J]. BioDrugs, 2021, 35(2): 201-214. DOI: 10.1007/s40259-021-00468-9.
|
| 14. |
Lam BL, Feuer WJ, Davis JL, et al. Leber hereditary optic neuropathy gene therapy: adverse events and visual acuity results of all patient groups[J]. Am J Ophthalmol, 2022, 241: 262-271. DOI: 10.1016/j.ajo.2022.02.023.
|
| 15. |
Subramaniam MD, Chirayath RB, Iyer M, et al. Mesenchymal stem cells (MSCs) in Leber's hereditary optic neuropathy (LHON): a potential therapeutic approach for future[J]. Int Ophthalmol, 2022, 42(9): 2949-2964. DOI: 10.1007/s10792-022-02267-9.
|
